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likelihood of suicide, absenteeism, and the hospitalisation rate. The reimburse-
ment of Seroquel XR® could generate annual budget savings of PLN 8.6 million (
2150 thousands Euro), if Seroquel XR® were used in 31% of quetiapine-treated
patients with schizophrenia. The maximum savings resulting from the reimburse-
ment of quetiapine prolonged release tablets (Seroquel XR®) could amount to PLN
27.6 million (6900 thousands Euro) per year. CONCLUSIONS: The reimbursement of
Seroquel XR® with the reimbursement limit at the level of the reimbursement limit
for normal tablets of quetiapine is profitable for the state budget – it will not only
bring budgetary savings, but also allow patients to return to active life, which is
crucial in the case of schizophrenia.
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OBJECTIVES: To estimate the economic consequences of replacing Seroquel (the
normal tablets of quetiapine) with Seroquel XR® in the treatment of bipolar disor-
der in Poland. METHODS: Based on the established model of the economic conse-
quences of bipolar disorder treatment, we calculated the cost of treating bipolar
disorder with quetiapine in Poland. Expenditures for the purchase of medicines,
hospital costs and the costs of lost productivity were highlighted. The analysis was
performed from a societal perspective, taking into account the Payer’s perspective,
in three–year time horizon. RESULTS: The use of Seroquel XR® will decrease hos-
pitalisation rate and length of hospitalisation, what will reduce direct costs of
bipolar disorder treatment by PLN 645 thousands (161 thousands Åuro). The use of
Seroquel XR® will increase the population of patients who comply with the recom-
mended treatment, which will reduce the likelihood of suicide, absenteeism, and
the disability pension. The budget savings related to indirect costs reduction are
estimated at PLN 15,3 million (3825 thousands Euro). Moreover, the reimursement
of Seroquel XR® would decrease the social transfers by PLN 157,6 thousands (39,4
thousands Euro) in comparison to current scenario. CONCLUSIONS: The reim-
bursement of Seroquel XR® with the reimbursement limit at the level of the reim-
bursement limit for normal tablets of quetiapine is profitable for the state budget –
it will not only bring budgetary savings, but also allow patients to return to active
life, which is crucial in the case of bipolar disorder.
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OBJECTIVES: Schizophrenia is a debilitating chronic psychiatric illness with a con-
siderable impact on the patient and the patient’s environment, in terms of mor-
bidity, mortality, human suffering and societal costs. Currently, little is known of
the exact cost of relapse in schizophrenia. Our objective is to estimate cost of
relapse based on resource utilization data collected alongside a clinical trial.
METHODS: “Constatre” is a multicenter, open-label, randomized, active-control,
long-term study comparing risperidone long acting injectable treatment with oral
quetiapine, conducted from October 2004 to November 2007 at 124 sites in 25 coun-
tries (ClinicalTrials.gov identifier: NCT00216476). Information regarding Medical
Resource Utilization (MRU) during the three months following relapse was col-
lected for a subset of patients. To estimate the associated relapse related costs,
average purchase power parity adjusted country resource unit costs (2010 Euro)
were applied. RESULTS: Detailed MRU data were available for 63 patients spread
across Europe. The overall mean MRU cost per patient in the three months follow-
ing the relapse was €7592, of which 79% was related to psychiatric hospitalisation.
68% of the relapsed patients were hospitalized, for on average 38.8 days, represent-
ing a total cost of €9117 (range €277 - €20,868) per hospitalised patient. 5% of the
patients were in day-clinic, on average for 41.3 days, representing a cost of €5829
per patient. The majority (60%) of the relapsed patients had outpatient visits, rep-
resenting a mean cost per patient of €1834, mainly to psychiatrists (57% of patients,
average  14.5 visits) and nurses (10% of patients, average  105.9 visits).
CONCLUSIONS:Costs related to relapse of schizophrenic patients are considerable,
and mainly driven by psychiatric hospitalisation. Antipsychotic treatment that
prevents or reduces relapse and psychiatric hospitalisation can have a major im-
pact on the total schizophrenia related treatment cost.
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OBJECTIVES: To compare the differences in health care costs between alcohol or
opioid-dependent patients who were treated with pharmacological (’Any Medica-
tion’) and non-pharmacological substances (’No Medication’). METHODS: A retro-
spective analysis was conducted using a large U.S. health plan claims database
from 2005 to 2009. Continuously eligible patients with at least one claim of alcohol/
opioid dependence during the identification period, and an alcohol/opioid use dis-
order diagnosis during the baseline period were included. Propensity score match-
ing (PSM) was applied to compare the risk-adjusted outcomes between the ’Any
Medication’ and ’No Medication’ cohorts. Baseline differences in age, gender, re-
gion, comorbidity scores, socioeconomic status, baseline health care utilization
and costs were controlled. RESULTS: During the pre-index period, for both alcohol
and opioid dependent patients, those in the ’Any Medication’ cohort had more
distinct psychiatric diagnoses, and were more likely to have Elixhauser Index
Scores of higher than 3, when compared to patients from the ’No Medication’
cohort. After adjusting baseline patient and clinical characteristics, 10,376 alcohol-
dependent patients were matched from each cohort. Patients who were treated
without pharmacological medication had more rehabilitation time, a higher detox-
ification cost burden ($1,350,000 per 1000 patients), and higher total health care
costs, compared to patients who were treated with pharmacological medication.
Similarly, there were 6,658 patients from each cohort matched for opioid-depen-
dent patients. Patients in the ’No Medication’ cohort incurred higher total health
care costs than patients in the ’Any Mediation’ cohort ($14,353,000 vs. $ 10,192,000
per 1000 patients) during the post-index period. CONCLUSIONS: After controlling
for confounders such as demographic factors, comorbid conditions and baseline
health care utilization, we showed that pharmacological medication treatments
were associated with lower health care costs than non-pharmacological substance
treatment for both alcohol and opioid-dependent patients.
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OBJECTIVES: Substance abuse (SA) represents a significant public health problem
that impacts tens of millions of persons in the US and imposes over $400 billion in
annual economic costs on a national basis in the form of lost productivity, prema-
ture death, criminal activity and use of medical care. The objective of this study
was to estimate the economic costs associated with drug and alcohol abuse for
Washington State in 2005.METHODS:We used standard cost of illness (COI) meth-
ods, relying on the prevalence approach, to estimate the costs of SA in six areas,
including mortality, morbidity, treatment costs, crime, and health care. We ob-
tained data for the analysis from various sources, including the Washington State
Health Department, the National Survey on Drug Use and Health, the State Depart-
ment of Corrections, and the Washington Association of County Sheriffs, and the
Washington State Department of Transportation. RESULTS: We estimated costs of
SA for 2005 for Washington State at $5.21 billion, $832 per non-institutionalized
person in the state. Alcohol abuse accounted for 56% of total costs. The per-capita,
inflation-adjusted costs increased by 47% from 1996. Categories accounting for the
greatest costs were mortality ($2.03 billion), crime ($1.09 billion), morbidity ($1.03
billion) and health care ($791 million). There were 3,224 deaths (7% of all deaths),
89,000 years of productive life lost, and 29,000 hospital discharges in 2005 in Wash-
ington associated with SA. CONCLUSIONS: SA imposes significant costs on society.
Its economic costs far outweigh the resources expanded to treat persons with SA.
For every $1 dollar the state collected in tax revenue for treatment from alcohol
sales in 2005, $20 in economic loss was incurred from alcohol abuse. Renewed
attention needs to be directed at finding more effective ways to reduce the eco-
nomic and human loss arising from SA.
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OBJECTIVES: This comprehensive review was conducted to report existing evi-
dence from published studies evaluating the economic burden of attention deficit
hyperactivity disorder (ADHD) in children and adolescents in Europe.METHODS:A
systematic search of electronic literature databases (EMBASE and MEDLINE), was
conducted from January 2001 to June 2011 to identify economic studies on ADHD in
children and adolescents in Europe. All economic studies in English language,
regardless of design and intervention were included. Eligibility of trials was as-
sessed by two reviewers with any discrepancy reconciled by a third, independent
reviewer. RESULTS: A total of 591 citations were retrieved out of which eight met
pre-defined inclusion criteria. Five studies were cost-analyses while three were
cost-effectiveness analyses. In Germany, the total direct costs for ADHD were €158
million in 2002 which increased to €287 million in 2006 with inpatient treatment
costs comprising approximately 40% of the total direct costs in 2006 (Wehmeier
2009). Other contributors to total direct costs included hospitalisations, special
health-care services, comorbidities, and physician visits (Ridder 2006). The total
projected costs of ADHD in Germany during 2012 are estimated to be €311 million
(Schlander 2007). The mean annual direct medical costs of ADHD patients with
psychiatric comorbidities were €5908 compared to €974 for ADHD alone in the The
Netherlands (Roijen 2007). The cost-effectiveness studies retrieved primarily fo-
cused on atomoxetine (ATX) and methylphenidate (MPH). ATX was found to be
more cost-effective than MPH in the UK (ICER of £15 224 per QALY gained) (Cottrell
2008) as well as in Spain (ICER of €34 308 per QALY gained) (Hong 2009).
CONCLUSIONS:ADHD is associated with substantial fiscal burden in Europe. Since
2002, a trend of increase in direct costs has been observed which may be due to
increasing demand for healthcare services, and presence of comorbidities.
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